6 358

Cited 2 times in

Prevalence and Management of Lower Urinary Tract Symptoms in Methamphetamine Abusers: An Under-Recognized Clinical Identity

DC FieldValueLanguage
dc.contributor.author구교철-
dc.contributor.author김장환-
dc.contributor.author나군호-
dc.contributor.author마상열-
dc.contributor.author이동훈-
dc.contributor.author정병하-
dc.contributor.author홍성준-
dc.date.accessioned2015-01-06T16:28:51Z-
dc.date.available2015-01-06T16:28:51Z-
dc.date.issued2014-
dc.identifier.issn0022-5347-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/98184-
dc.description.abstractPURPOSE: We investigate the prevalence of lower urinary tract symptoms in a cohort of methamphetamine abusers, and assess the therapeutic efficacy of α-blockers and anticholinergics. MATERIALS AND METHODS: From May 2011 to March 2013, 78 male methamphetamine abusers diagnosed with methamphetamine addiction were identified at the National Forensic Hospital, Korea. The I-PSS (International Prostate Symptom Score) with consultation was used to investigate the prevalence of lower urinary tract symptoms, defined as total I-PSS 8 or greater and quality of life index score of 2 or greater. These values for methamphetamine abusers were compared to those of 71 age matched controls. α-Blockers and anticholinergics were administered to methamphetamine abusers with lower urinary tract symptoms according to predominant voiding and storage symptoms based on voiding-to-storage subscore ratios. For methamphetamine abusers with no response, defined as a reduction of 4 or less in total I-PSS, an alternative drug or combination was administered. Efficacy was assessed based on a 4-week interval. RESULTS: The median periods of methamphetamine abuse and abstinence were 18.1 years and 5.7 months, respectively. Methamphetamine abusers showed a higher prevalence of lower urinary tract symptoms compared to controls (77% vs 15%, p <0.001), with higher I-PSS and quality of life index score (13.3 vs 5.6 and 2.9 vs 0.9, respectively; p <0.001). Anticholinergics showed the greatest effect on I-PSS reduction with overall response rates for α-blockers, anticholinergics and combinations of 13%, 61% and 14%, respectively. Seven (12%) methamphetamine abusers did not respond to any therapy. CONCLUSIONS: Lower urinary tract symptoms were highly prevalent among methamphetamine abusers. Our results imply that pathological dopaminergic mechanisms have a role in methamphetamine associated lower urinary tract symptoms. Moreover, first line anticholinergics and prompt combination with α-blockers conferred the most therapeutic benefit to nonresponders.-
dc.description.statementOfResponsibilityopen-
dc.format.extent722~726-
dc.relation.isPartOfJOURNAL OF UROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdrenergic alpha-Antagonists/therapeutic use*-
dc.subject.MESHAdult-
dc.subject.MESHCase-Control Studies-
dc.subject.MESHCholinergic Antagonists/therapeutic use*-
dc.subject.MESHHumans-
dc.subject.MESHLower Urinary Tract Symptoms/chemically induced*-
dc.subject.MESHLower Urinary Tract Symptoms/drug therapy*-
dc.subject.MESHLower Urinary Tract Symptoms/epidemiology-
dc.subject.MESHMale-
dc.subject.MESHMethamphetamine/toxicity*-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrevalence-
dc.subject.MESHQuality of Life-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.subject.MESHSubstance-Related Disorders/complications*-
dc.subject.MESHTreatment Outcome-
dc.titlePrevalence and Management of Lower Urinary Tract Symptoms in Methamphetamine Abusers: An Under-Recognized Clinical Identity-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨기과학)-
dc.contributor.googleauthorKyo Chul Koo-
dc.contributor.googleauthorDong Hoon Lee-
dc.contributor.googleauthorJang Hwan Kim-
dc.contributor.googleauthorKoon Ho Rha-
dc.contributor.googleauthorByung Ha Chung-
dc.contributor.googleauthorSung Joon Hong-
dc.contributor.googleauthorSang Yol Mah-
dc.identifier.doi10.1016/j.juro.2013.08.020-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02742-
dc.contributor.localIdA00188-
dc.contributor.localIdA00855-
dc.contributor.localIdA01227-
dc.contributor.localIdA01344-
dc.contributor.localIdA03607-
dc.contributor.localIdA04402-
dc.relation.journalcodeJ01921-
dc.identifier.eissn1527-3792-
dc.identifier.pmid23968967-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0022534713051409-
dc.subject.keywordlower urinary tract symptoms-
dc.subject.keywordmethamphetamine-
dc.subject.keywordprevalence-
dc.subject.keywordtreatment outcome-
dc.contributor.alternativeNameKoo, Kyo Chul-
dc.contributor.alternativeNameKim, Jang Hwan-
dc.contributor.alternativeNameRha, Koon Ho-
dc.contributor.alternativeNameMah, Sang Yol-
dc.contributor.alternativeNameLee, Dong Hoon-
dc.contributor.alternativeNameChung, Byung Ha-
dc.contributor.alternativeNameHong, Sung Joon-
dc.contributor.affiliatedAuthorLee, Dong Hoon-
dc.contributor.affiliatedAuthorKoo, Kyo Chul-
dc.contributor.affiliatedAuthorKim, Jang Hwan-
dc.contributor.affiliatedAuthorRha, Koon Ho-
dc.contributor.affiliatedAuthorMah, Sang Yol-
dc.contributor.affiliatedAuthorChung, Byung Ha-
dc.contributor.affiliatedAuthorHong, Sung Joon-
dc.rights.accessRightsfree-
dc.citation.volume191-
dc.citation.number3-
dc.citation.startPage722-
dc.citation.endPage726-
dc.identifier.bibliographicCitationJOURNAL OF UROLOGY, Vol.191(3) : 722-726, 2014-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.